Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

CBAK Energy Technology Inc

Inspira Technologies Oxy BHN Ltd

Innoviz Technologies

CarLotz

Metromile

Powerbridge Technologies Co Ltd

Reddit penny stocks to watch today. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 Hot Reddit Stocks To Watch

MORRISVILLE, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, previously referred to as LIQ861. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. Tentative approval indicates that YUTREPIA has met all regulatory standards for quality, safety and efficacy required for approval in the United States.

FDA Grants Tentative Approval for Liquidia's YUTREPIA™ (Treprostinil) Inhalation Powder

-   Increased adoption of generic Treprostinil Injection by patients, physicians and payers -   Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities -   Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Clear Channel Outdoor Holdings

Digital Brands Group Inc

Kala Pharmaceuticals

4 penny stocks to watch this week. The post 4 Top Penny Stocks To Watch After FOMC Meeting In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch After FOMC Meeting In November

Agenus

Corvus Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Tonix Pharmaceuticals Hld

Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For November With Potential Biotech Catalysts

MORRISVILLE, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format.

Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

No Form 483 observations were issued during 5-day inspection No Form 483 observations were issued during 5-day inspection

FDA Completes On-site Pre-Approval Inspection of Liquidia's Morrisville, North Carolina Facility

The shares of Liquidia Corp (NASDAQ: LQDA) increased by over 18% during intraday trading. This is why it happened.

Liquidia Shares Increase Over 18% Intraday: Why It Happened

Liquidia Corporation's (LQDA) CEO Damian deGoa on Q2 2021 Results - Earnings Call Transcript

Shares of Liquidia (NASDAQ:LQDA) fell 0.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 73.47% year over year to ($0.13), which beat the estimate of ($0.15).

Liquidia: Q2 Earnings Insights

MORRISVILLE, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter ended June 30, 2021. The Company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss the second quarter financial results and provide a corporate update.

Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update

LQDA is trying to bring a Tyvaso competitor to the market that allegedly works better. United is doing all it can to stop that.

Liquidia: Martine Rothblatt's United Therapeutics Is Tough To Beat

MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial results and provide a corporate update.

Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021

MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH). The FDA confirmed that the resubmission was a complete, class 2 response to the previous action letter issued on November 24, 2020. The FDA set a PDUFA goal date of November 7, 2021.

Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.

Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous

Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration

Liquidia Technologies, Inc. (LQDA) CEO Damian deGoa on Q1 2021 Results - Earnings Call Transcript

- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery - Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder - Improved financial position with private placement and access to new credit facility - Company to host webcast and conference call today at 8:30 a.m. ET

Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the NDA in November 2020 indicating that the application was incomplete and not ready for approval in its present form. Liquidia and the FDA held a Type A meeting in January 2021 to discuss the CRL and the requirements for the NDA resubmission.

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss financial results and provide a corporate update.

Liquidia Corporation to Report First Quarter 2021 Financial Results on May 13, 2021

RESEARCH TRIANGLE PARK, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8,626,037 shares of common stock at a purchase price of $2.52 per share, the closing price per share of common stock on April 12, 2021. The private placement is expected to close today and yield gross proceeds of approximately $21.7 million. The investor group was led by Caligan Partners LP and includes participation by existing directors Paul Manning and Roger Jeffs.

Liquidia Corporation Announces $21.7 Million Private Placement

RESEARCH TRIANGLE PARK, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Treprostinil Injection, a generic form of Remodulin®, will soon be available for subcutaneous (“SC”) administration to treat patients diagnosed with pulmonary arterial hypertension (“PAH”).

Liquidia Announces Generic Treprostinil Injection Will Be Available for Subcutaneous Route of Administration

Liquidia Technologies, Inc. (LQDA) CEO Damian deGoa on Q4 2020 Results - Earnings Call Transcript

-  Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH -  Clarified path towards submitting response to CRL for LIQ861 in mid-2021 -  Reducing net annual spending more than 40% in 2021 compared to 2020 cash burn -  Company to host webcast and conference call today at 8:30 a.m. ET

Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Corporate Update

RESEARCH TRIANGLE PARK, N.C., March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate update.

News for Liquidia Technologies Inc Stock (LQDA)